Criteria | Sensitivity (%) | Specificity (%) |
All subjects, n = 248 | ||
1987 ACR criteria | 51 | 91 |
1987 ACR criteria+anti-CCP | 55 | 91 |
CCP 7 criteria | 77 | 79 |
CCP 6 criteria | 74 | 81 |
Subjects with arthritis symptoms ⩽6 months, n = 66 | ||
1987 ACR criteria | 25 | 86 |
1987 ACR criteria+anti-CCP | 44 | 86 |
CCP 7 criteria | 63 | 72 |
CCP 6 criteria | 63 | 72 |
Subjects with arthritis symptoms >6 months, n = 182 | ||
1987 ACR criteria | 58 | 93 |
1987 ACR criteria+anti-CCP | 58 | 93 |
CCP 7 criteria | 81 | 82 |
CCP 6 criteria | 77 | 85 |
ACR, American College of Rheumatology; anti-CCP, antibodies to cyclic citrullinated peptide; CCP 7 (criteria), removing rheumatoid nodules alone while substituting anti-CCP; CCP 6 (criteria), removing both rheumatoid nodules and erosions while substituting anti-CCP.
*Calculation for specificity performed using only individuals diagnosed as “not RA” by the rheumatologist at most recent follow-up.